Your browser does not allow JavaScript!
JavaScript is necessary for the proper functioning of this website. Please enable JavaScript or use a modern browser.
Open Science Slovenia
Open Science
DiKUL
slv
|
eng
Search
Browse
New in RUL
About RUL
In numbers
Help
Sign in
Treatment of canine cognitive dysfunction with novel butyrylcholinesterase inhibitor
ID
Zakošek, Maja
(
Author
),
ID
Prpar Mihevc, Sonja
(
Author
),
ID
Štrbenc, Malan
(
Author
),
ID
Košak, Urban
(
Author
),
ID
German Ilić, Ilija
(
Author
),
ID
Trontelj, Jurij
(
Author
),
ID
Žakelj, Simon
(
Author
),
ID
Gobec, Stanislav
(
Author
),
ID
Pavlin, Darja
(
Author
),
ID
Majdič, Gregor
(
Author
)
PDF - Presentation file,
Download
(1,34 MB)
MD5: 2A7E6FFD649C1E4BB4A045BC8C9556C4
Description: Open access
URL - Source URL, Visit
https://www.nature.com/articles/s41598-021-97404-2
Image galllery
Abstract
Canine cognitive dysfunction (CCD) is common in aged dogs and has many similarities with Alzheimer’s disease. Unfortunately, like Alzheimer’s disease, CCD cannot be cured. In the present study, we treated dogs with CCD with our newly developed and characterized butyrylcholinesterase inhibitor (BChEi). Seventeen dogs were randomized into two groups (treated with BChEi and untreated) and followed for 6 months at regular check-ups. The dogs’ cognitive status was determined by a Canine Dementia Scale (CADES) questionnaire and two cognitive tests. In dogs with moderate cognitive impairment, treatment caused significant improvement in the clinical rating of cognitive abilities and the performance-based tests of cognitive functioning when compared to the untreated group (p < 0.001). Dogs treated with BChEi showed markedly improved cognitive function with enhanced quality of life. No side effects were observed in the treated dogs with moderate cognitive impairment. According to the results of this preliminary study, there is an indication that novel BChEi may be a promising drug for the treatment of CCD in dogs and may be an interesting candidate for the treatment of Alzheimer's disease in humans. However, further clinical studies are needed to confirm this.
Language:
English
Keywords:
Alzheimer’s disease
,
butyrylcholinesterase
,
butyrylcholinesterase inhibitor
,
canine cognitive dysfunction
,
canine dementia scale
,
dogs
Work type:
Article
Typology:
1.01 - Original Scientific Article
Organization:
VF - Veterinary Faculty
FFA - Faculty of Pharmacy
Publication status:
Published
Publication version:
Version of Record
Submitted for review:
15.12.2020
Article acceptance date:
17.08.2021
Publication date:
13.09.2021
Year:
2021
Number of pages:
10 str.
Numbering:
Vol. 11, art. 18098
PID:
20.500.12556/RUL-131180
UDC:
636.7.09:616.892
ISSN on article:
2045-2322
DOI:
10.1038/s41598-021-97404-2
COBISS.SI-ID:
77000195
Publication date in RUL:
23.09.2021
Views:
933
Downloads:
182
Metadata:
Cite this work
Plain text
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Copy citation
Share:
Record is a part of a journal
Title:
Scientific reports
Shortened title:
Sci. rep.
Publisher:
Nature Publishing Group
ISSN:
2045-2322
COBISS.SI-ID:
18727432
Licences
License:
CC BY 4.0, Creative Commons Attribution 4.0 International
Link:
http://creativecommons.org/licenses/by/4.0/
Description:
This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:
13.09.2021
Projects
Funder:
ARRS - Slovenian Research Agency
Project number:
P4-0053
Name:
Endokrini, imunski in encimski odzivi pri zdravih in bolnih živalih
Funder:
ARRS - Slovenian Research Agency
Project number:
P1-0208
Name:
Farmacevtska kemija: načrtovanje, sinteza in vrednotenje učinkovin
Funder:
EC - European Commission
Name:
European Regional Development Fund
Acronym:
Sonja Perpar Mihevc
Similar documents
Similar works from RUL:
Similar works from other Slovenian collections:
Back